Organogenesis Holdings Inc. ORGO

About Organogenesis Holdings Inc. (ORGO): stock profile, AI score and financials

Organogenesis Holdings Inc. (ORGO) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ORGO at 31.6/100 on a composite quality score built from its SEC filings, placing it at rank #2,427 of 2,925 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (11.1) and profitability (15.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 36.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Organogenesis Holdings Inc. reports quarterly revenue of $43.8M, net income of $-96.3M, an operating margin of -116.5%. Top institutional holders of ORGO by reported 13-F value include MORGAN STANLEY, Soleus Capital Management, L.P., BlackRock, based on the most recent SEC filings. ORGO trades on the Nasdaq exchange and files with the SEC under CIK 1661181. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ORGO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Organogenesis Holdings Inc. directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 1661181 →